Obefazimod shows efficacy and favourable safety in patients with moderate to severely active ulcerative colitis in a 96-week ...

Mineralys’ therapy at the 50mg dosage met its primary endpoint by demonstrating a 15.4 point reduction in SBP versus a 7.9 point reduction for placebo at week 12 (p=0.001). In both trials ...